Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05755906 · ClinicalTrials.gov registry record · Phase 3
A 12-week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler in Participants With Inadequately Controlled Asthma (LITHOS)
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 374
- Enrollment target
NCT05755906 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 374 participants.
The verdict
NCT05755906, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 374 participants
- Enrollment target
Study Summary
This is a 12-week study to evaluate the efficacy and safety of budesonide and formoterol fumarate metered dose inhaler relative to budesonide metered dose inhaler in adults and adolescents with inadequately controlled asthma.
Interventions
- DRUG BFF MDI 160/9.6 μg BID (320/19.2μg/day)
- DRUG BD MDI 160 μg BID (320 μg/day)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 374 participants |
| Start Date | 2023-02-27 |
| Est. Completion | 2024-11-19 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05755906
The ClinicalTrials.gov registry entry for NCT05755906 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 374 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which BFF MDI 160/9.6 μg BID (320/19.2μg/day) is the first listed.
NCT05755906 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05755906 about?
NCT05755906 is a clinical study titled "A 12-week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler in Participants With Inadequately Controlled Asthma (LITHOS)". This is a 12-week study to evaluate the efficacy and safety of budesonide and formoterol fumarate metered dose inhaler relative to budesonide metered dose inhaler in adults and adolescents with inadequately controlled asthma.
What is the current status of trial NCT05755906?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 374 participants. The study started on 2023-02-27. Estimated completion is 2024-11-19.
What interventions are being tested in trial NCT05755906?
The interventions under investigation include: BFF MDI 160/9.6 μg BID (320/19.2μg/day) (DRUG), BD MDI 160 μg BID (320 μg/day) (DRUG).
Who is sponsoring clinical trial NCT05755906?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.